RSS   Newsletter   Contact   Advertise with us

Regulus appoints William H. Rastetter to the board

Staff writer | La Jolla, Ca., USA | April 2, 2013
RegulusApril 2, 2013, La Jolla, Ca., USA - Regulus Therapeutics Inc., a biopharmaceutical company, announced that it has appointed William H. Rastetter to its board of directors.
Dr. Rastetter served as Chief Executive Officer of IDEC Pharmaceuticals from December 1986 through November 2003, and as Chairman from May 1996 to November 2003. Upon the merger of IDEC Pharmaceuticals and Biogen in November 2003, Dr. Rastetter served as Executive Chairman of Biogen Idec until the end of 2005.

From 2006 to 2013, Dr. Rastetter served as a partner in the venture capital firm, Venrock. Dr. Rastetter currently serves as the Chairman of the Board of Directors of Fate Therapeutics, Inc., Illumina, Inc., Neurocrine Biosciences and Receptos, Inc. He is the author of numerous scientific papers and patent applications in the fields of organic and bioorganic chemistry, protein and enzyme engineering, and biotechnology.

Dr. Rastetter holds a S.B. in Chemistry from the Massachusetts Institute of Technology and received his M.A. and Ph.D. in Chemistry from Harvard University.